InnoCare Appoints Dr. Manish Tandon as Vice President of Business Development

Oct. 12, 2020 03:20 UTC

BEIJING--(BUSINESS WIRE)-- InnoCare Pharma (HKEX: 09969), a clinical stage biopharmaceutical company, announced today that the Company has appointed Dr. Manish Tandon as Vice President of Business Development, reporting to the Co-founder, Chairman and CEO, Dr. Jasmine Cui. Dr. Tandon will be responsible for the Company’s business development strategy and execution, external collaborations, licensing and M&A.

Dr. Tandon has over 20 years of experience in the biotechnology space spanning business development, M&A and drug development. Before joining InnoCare, Dr. Tandon served as Vice President of business development, alliance management, new product planning and intellectual property at ArQule, an oncology-focused drug developer. Dr. Tandon has proven transactional expertise in bio-pharmaceutical industry. Most recently, Dr. Tandon played a key role in the acquisition of ArQule by Merck for $2.7 billion. Prior to that he successfully negotiated and executed two exclusive license agreements for derazantinib with Basilea Pharmaceutica and Sinovant Sciences.

“We are delighted to welcome Dr. Tandon to join InnoCare to enhance the Company’s business development competency. Dr. Tandon has rich experience in drug discovery & development and sharp business insights, and he has completed a series of impressive transactions in the field of M&A, licensing and external collaborations. His impressive experience will strengthen InnoCare’s business development capabilities,” said Dr. Jasmine Cui.

“I am excited to join InnoCare, a leading bio-pharmaceutical company with global vision. I am deeply impressed by the Company’s internal research capabilities, pipeline and the achievements during the past 5 years and look forward to partnering with our highly experienced leadership team to advance the Company’s business development goals to benefit patients worldwide,” said Dr. Tandon.

Dr. Tandon earned his Ph.D. in Organic Chemistry from Brown University and completed his postdoctoral research at Cornell University. Dr. Tandon earned his MBA from Questrom School of Business at Boston University. He received his bachelor’s degree in Chemistry from Delhi University.

About InnoCare Pharma

InnoCare Pharma is a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on lymphoma, solid tumors, and autoimmune disease with high unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, New Jersey, and Boston.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201011005064/en/

Contacts

Media
Chunhua Lu
86-10-66609879
chunhua.lu@innocarepharma.com

Investor Relations
86-10-66609999
ir@innocarepharma.com

 

Source: InnoCare Pharma

Back to news